publication date: Jun. 15, 2018

Guest Editorial The Trump administration “American Patients First” plan to reduce drug prices—Are American cancer patients first? Hagop Kantarjian

Hagop Kantarjian

Chairman, Department of Leukemia, MD Anderson Cancer Center

Baker Institute Special Fellow for Health Policies, Rice University Baker Institute

 

Mary Alma Welch

Mary Alma Welch

Manager, Advanced Practice Providers, Department of Leukemia, MD Anderson Cancer Center

 

In May 2018, President Trump announced his plan to lower drug prices. “We will have tougher negotiation, more competition, and much lower prices at the pharmacy counter. And it will start to take effect very soon,” he promised. The plan is outlined in a 40-page document by the U.S. Department of Health and Human Services titled “American Patients First—The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Cost.” (1)

The Food and Drug Administration followed with parallel plans to complement the administration’s strategies (2, 3). The HHS Secretary Alex Azar, a previous CEO of pharmaceutical company Eli Lilly, identified … Continue reading The Trump administration “American Patients First” plan to reduce drug prices—Are American cancer patients first?

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.